Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.50 |
| ▸ | HTR3B | O95264 | 3/20 | 0.50 |
| ▸ | HTR3A | P46098 | 3/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | S100A9 | P06702 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581044 | 1.00 | PNMT (0.54) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL28332854 | 0.98 | PNMT (0.52) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8370549 | 0.87 | PNMT (0.54) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8075846 | 0.86 | CA2 (0.41) | CYP3A4 | |
| SCHEMBL2343233 | 0.85 | PNMT (0.52) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30502958 | 0.85 | PNMT (0.52) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL294675 | 0.85 | PNMT (0.52) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2377120 | 0.83 | PNMT (0.50) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL2377117 | 0.83 | PNMT (0.50) | PNMTHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1644190 | 0.83 | CA1 (0.57) | PNMTHTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578577-A1 | Sulfonyl esters of tetrahydrocannabinol and derivatives thereof | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| US-7674922-B2 | Process for production of delta-9-tetrahydrocannabinol | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | claimed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| EP-1928853-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR Technology, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | claimed |
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | AMR TECHNOLOGY, INC. (US) | 2007-04-26 | — | — | US | claimed |
| WO-2007041167-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR TECHNOLOGY, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | claimed |
| EP-0255134-B1 | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | claimed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| CN-118103359-A | Preparation method of eribulin derivative | 江苏恒瑞医药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4415574-A | BACTERICIDES; MEDICINES; POTENTIATION OF SULFA DRUGS | S. A. PANMEDICA (FR) | 1983-11-15 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | CNR2, CNR1, HRH4 | PNMT 1505/4885HTR3E 858/4885HTR3B 1157/4885 |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | PNMT 112/4885HTR3E 32/4885HTR3B 2/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | PNMT 4283/4885HTR3E 251/4885HTR3B 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.